{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:13:37Z","timestamp":1778001217503,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:p>Asparaginase (ASNase) use as a tumour-inhibitor drug has changed completely the natural course of paediatric acute lymphoblastic leukaemia (ALL) in such a way that it represents a paradigm shift in ALL management. ASNase treatment emergence has significantly improved pathologic responses and increased survival rates of ALL patients. Although different ASNase forms are currently available, only the pegylated form (PEG-ASNase) is recommended by relevant clinic guides. PEG-ASNase form shows longer elimination half-life, reducing the number of administrations, along with an enhanced safety profile. In spite of all of these advantages, PEG-ASNase elevated cost limits enormously its use. PEG-ASNase is commercialised as a lyophilised powder which according to the manufacturer it is stable for 24\u2009hours once reconstituted, as a result, the leftover is usually discarded. In this study we analysed the enzymatic stability of reconstituted PEG-ASNase after conservation in three different temperature conditions for 5 and 14\u2009days, aiming to take advantage of the remaining leftover for the subsequent administration.<\/jats:p>\n                  <jats:p>\u2003Our results have shown that PEG-ASNase is stable at 4\u00b0C, \u221220\u00b0C and \u221280\u00b0C for at least 14\u2009days, retaining the 95% from the initial enzymatic activity in all three storage temperatures. According to our results, it is feasible to reuse the remaining content of PEG-ASNase vial after reconstitution, which means a 50% reduction of its cost for paediatric patient treatment and, consequently, removes the main barrier to use this drug in a wider population.<\/jats:p>","DOI":"10.1177\/1078155220950001","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T01:44:50Z","timestamp":1598579090000},"page":"1102-1105","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Extended enzymatic stability of reconstituted lyophilized PEG-asparaginase in vials"],"prefix":"10.1177","volume":"27","author":[{"given":"Mar\u00eda M","family":"Vi\u00f1a-Romero","sequence":"first","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Hospital Universitario Nuestra Se\u00f1ora de la Candelaria, Santa Cruz de Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Ramos D\u00edaz","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC), La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3nathan","family":"Gonz\u00e1lez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Complejo Hospitalario Universitario de Canarias, La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Nazco-Casariego","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Complejo Hospitalario Universitario de Canarias, La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0750-8267","authenticated-orcid":false,"given":"J\u00e9sica","family":"D\u00edaz-Vera","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Complejo Hospitalario Universitario de Canarias, La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Guti\u00e9rrez-Nicol\u00e1s","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, Complejo Hospitalario Universitario de Canarias, La Laguna, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"bibr1-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1710-5"},{"key":"bibr2-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1126\/science.122.3168.501"},{"key":"bibr3-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1038\/1911114a0"},{"key":"bibr4-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198609113151101"},{"key":"bibr5-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(68)90028-4"},{"key":"bibr6-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1211"},{"key":"bibr7-1078155220950001","unstructured":"Sociedad Espa\u00f1ola de Hematolog\u00eda y Oncolog\u00eda Pedi\u00e1trica y Programa para el estudio de la Terap\u00e9utica en Hemopat\u00eda Maligna.\n                      Recomendaciones terap\u00e9uticas LAL\/SEHOP-PETHEMA 2013\n                      . Versi\u00f3n 2.0, https:\/\/www.sehh.es\/images\/stories\/recursos\/2014\/documentos\/guias\/LAL_SEHOP_PETHEMA_2013.pdf (2014, accessed 29 July 2020)."},{"key":"bibr8-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.12.1977"},{"key":"bibr9-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1986"},{"key":"bibr10-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245951"},{"key":"bibr11-1078155220950001","unstructured":"Pegaspargase (Oncaspar\u00ae) \u2013 EPAR product information. EMEA\/h\/c\/003789, www.ema.europa.eu\/documents\/product-information\/oncaspar-epar-product-information_en.pdf (2016, accessed 29 July 2020)."},{"key":"bibr12-1078155220950001","author":"Lanvers-Kaminsky C","journal-title":"Therapeutic Drug Monitoring"},{"key":"bibr13-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25319"},{"key":"bibr14-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26123"},{"key":"bibr15-1078155220950001","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27458"},{"key":"bibr16-1078155220950001","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.073510"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220950001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220950001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220950001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:32Z","timestamp":1777688612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220950001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/1078155220950001"],"URL":"https:\/\/doi.org\/10.1177\/1078155220950001","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]}}}